Patent · US Active

Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes

US7598281B2 · kind B2 · utility

0Cited by

0References

10Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Heiner Glombik · Hofheim, DE
Christian Stapper · Mainz, DE
Eugen Falk · Frankfurt am Main, DE
Stefanie Keil · Frankfurt am Main, DE
Hans-Ludwig Schaefer · Frankfurt am Main, DE
Wolfgang Wendler · Bad Camberg, DE
Stephanie Knieps · Pocking, DE

Key dates

Filing date	Feb 7, 2007
Grant date	Oct 6, 2009
Priority date	—
Expiry date	Apr 12, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P9/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with arylcycloalkyl-substituted alkanoic acid derivatives and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of the formula Iwherein the various substituent R-groups are more specifically defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.